The Study of Dimenhydrinate Antihistamine`s Effects on Liver`s Tissue and Enzymes in Male Rats
Subject Areas : Journal of Animal BiologyO. Naemi 1 , K. Roshanayi 2 , F. Jamalloo 3 , M. Ahmadifar 4
1 - Department of Biology, Qom Branch, Islamic Azad University, Qom, Iran
2 - Department of Biology, Qom Branch, Islamic Azad University, Qom, Iran
3 - Department of Biology, Qom Branch, Islamic Azad University, Qom, Iran
4 - Department of Embryology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
Keywords: liver, Rat, Dimenhydramine, Antihistamine,
Abstract :
In this study, we checked the distractive effects of dimenhydramine antihistamine on liver`s tissue and enzymes thereinafter excessive prescription. Dimenhydramine is a drug with anti-gastric reflux and anti-nausea effects usually used in trip for sensitive persons. This drug absorbed easily from oral usage and during 24 h excreted from kidneys and it has hepatic metabolism. We used 40 male Wistar adult rats whit 250+20 weighting that grouped into four groups. The control group was without treatment and the other fed with 2.5, 5, 7.5 mg/kg of dienhydramine doses daily within 28 d. After the examination procedure, rats became unconscious with ether, blood sampling and liver`s biopsy were done and sent to the laboratory for more study. Comparing the enzyme levels of ALT, AST, and ALP in the treatment and control groups, there was a rise in the enzyme levels as a result of liver damage caused by taking dimenhydramine antihistamine. Observing the microscopic slides of the liver tissue of the treatment group, it suggests sinusoid destruction, the loss of bile ducts, irregular placement of adjacent cells and the absence of Kupffer cells, which in turn confirms the negative effect of this drug on liver tissue. Like other medications, dienhydramine can exert adversary effects as well as positive effects. Since one of the tissues which are susceptible to this effect is liver, we must bear in mind when it comes to prescribing this medication.
1. Abernathy C.O., Zimmerman H.J., Ishak K.G., Utili R., Gillespie J., 2003. Drug - induced cholestasis in the perfused rat liver and its reversal by tauroursodeoxycholate: an ultrastructural study. Proceedings of the Society for Experimental Biology and Medicine, 199(1): 54-8.
2. Androli T., Carpenter C., Griggs R., Benjamin I., 2007. Diseases of the Liver and Biliary System. in: Cecil'sEssentials of Medicine. 7th ed. USA: WB Saunders Company, 23.
3. Arteel G., Marsano L., Mendez C., Bentley F., McClain C.J., 2003. Advances in alcoholic liver disease. Best Practice & Research Clinical Gastroenterology, 17: 625–47.
4. Azer S.A., Stacey N.H., 2001. Current concept of hepatic uptake, intracellular transport and biliary secretion of bile acids: physiological basis and pathophysiological changes in cholestatic liver dysfunction. Journal of Gastroenterology Hepatology, 11(4): 396-407.
5. Bloomgarden Z.T., 2005: Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and famotidine liver disease. Diabetes Care, 28: 1518-1523.
6. Becker U., Deis A., Sorensen T.I., 2009. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology, 23: 1025–9.
7. Bellentani S., Tiribelli C., Saccoccio G., 2011. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology, 20: 1442–9.
8. Bellentani S., Saccoccio G., Costa G., 2008. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut, 41: 845–50.
9. Bouchier I.A.D., Hislop W.S., Prescott R.J., 2007. A prospective study of alcoholic liver disease and mortality. Journal of Hepatology, 16: 290–7.
10. Bell H., Jahnsen J., Kittang E., Raknerud N., Sandvik L., 2004. Long-term prognosis of patients with alcoholic liver cirrhosis: a 15-year follow-up study of 100 Norwegian patients admitted to one unit. Scandinavian Journal of Gastroenterology, 39: 858– 63.
11. Brunt E.M., Tiniakos D.G., 2010. Histopathology of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 16: 5286-5296.
12. Charde M., Kurane P., Dhabale P., 2015. Development of Stability Indicating Assay Method for Estimation of Ibuprofen and Famotidine in Combined Dosage Form in Tablet. International Journal of Advances in Pharmaceutical Analysis, 5(4): 85-92
13. Corrao G., Arico S., Zambon A., 2010. Is alcohol a risk factor for liver cirrhosis in HBsAg and anti-HCV negative subjects? Collaborative Groups for the Study of Liver Diseases in Italy. Journal of Hepatology, 27: 470–6.
14. Glass J.R., Sproule B.A., Herrmann N., Busto U.E., 2008. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a ran- domized, placebo-controlled trial. Journal of Clinical Psychopharmacology, 28: 182–188.
15. Kuitunen M., Kukkonen K., Juntunene-Backman K., Korpela R., Poussa T., Tuure T, 2009. Probiotics prevent associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. Journal of Allergy and Clinical Immunology, 123: 335-41.
16. Kerr J.B., Maddocks S., Sharpe R.M., 2003. SGPT and SGOT have independent, synergistic and stage-dependent effects upon Liver in the rat Liver. Journal of Cell and Tissue Research, 268:179–189.
17. Karanth J., Jeevaratnam K. 2010. Effect of carnitine supplementation on mitochondrial enzymes in liver and skeletal muscle of rat after dietary lipid manipulation and physical activity. Indian Journal of Experimental Biology, 48: 503-510.
18. Luper S.A. 2005. Review of plants used in the treatment of liver disease. Alternatvie Medicine Review, 3: 40-2.
19. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., 2001. Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 50: 2002-1850
20. Neuberger J., Schulz K.H., Day C., 2002. Transplantation for alcoholic liver disease. Journal of Hepatology, 36: 130–7.
21. Pageaux G.P., Bismuth M., Perney P., 2003. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? Journal of Hepatology, 38: 629–34.
22. Palabiyik I.M., Onur F., 2007. Simultaneous Spectrophotometric Determination of Pseudoepedrine Sulphate and Loratadine in a Pharmaceutical Preparation Using Chemometric Techniques. Journal of Faculty of Pharmacy of Ankara University, 36(3): 171-182.
23. Poullis A.P., Shetty A.K., Risley P.D., Collinson P.O., Mendall M.A., 2003. Effect of the CD14 promoter polymorphism on liver function tests and its association with alcohol and obesity. European Journal of Gastroenterology & Hepatology, 15: 1317–22.
24. Rouault T.A., 2003. Hepatic iron overload in alcoholic liver disease: why does it occur and what is its role in pathogenesis? Alcohol, 30: 103–6.
25. Stickel F., Osterreicher C.H., 2006. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol, 41: 209– 24.
26. Sherlac S., 2001. Discases of the liver and bilary system 8 edition black Well scientific. Oxford, P: 1-12
27. Safdar K., Schiff E.R., Alcohol and hepatitis C., Semin Liver Dis 2004; 24: 305– 15. 35) Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2014; 24: 217–32.
28. Stewart S., Jones D., Day C.P., 2001. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends in Molecular Medicine, 7: 408–13.
29. Sorensen T.I., Orholm M., Bentsen K.D., Hoybye G., Eghoje K., Christoffersen P., 2012.Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet, 2: 241–4.
30. Tome S., Lucey M.R., 2004. Review article: current management of alcoholic liver disease. Alimentary Pharmacology & Therapeutics, 19: 707–14.
31. Teli M.R., Day C.P., Burt A.D., 2011. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet, 346: 1562–3.
32. Zintzaras E., Stefanidis I., Santos M., Vidal F., 2006. Do alcohol-metabolizing enzyme gene polymorphism increase the risk of alcoholism and alcoholic liver disease? Hepatology, 43: 352–61.
_||_